XOMA Royalty: Preferreds Still Offer Compelling Income Despite Call Risk

Why It Matters

The preferred’s strong yield and growing royalty pipeline provide a rare blend of biotech upside and reliable cash flow, appealing to income‑focused investors in a low‑rate environment.

Key Takeaways

• XOMAO offers 8.3% cumulative preferred yield.
• New 24 royalty assets added in 2025.
• Section 174 tax attributes may boost after‑tax cash.
• Dividend durability hinges on XOMA’s balance sheet health.
• Preferreds carry call risk but remain income‑focused.

Pulse Analysis

XOMA Royalty Corporation operates a niche business model that monetizes royalty streams, milestone payments, and licensing fees from biotech and pharmaceutical partners. By aggregating these rights, XOMA creates a diversified, non‑dilutive cash‑flow engine that is largely insulated from the volatility of any single drug development program. This structure not only offers investors exposure to the high‑growth biotech sector but also generates predictable revenue that underpins its preferred dividend.

The 8.375% cumulative preferred, listed as XOMAO, delivers an 8.3% yield—significantly above average preferred rates in the current market. While the security carries call risk, its dividend durability is anchored by XOMA’s robust balance sheet and the steady inflow of royalty payments. Analysts view the preferred’s yield as sustainable provided the company maintains its asset acquisition pace and manages payout obligations. The cumulative feature further protects investors by accruing unpaid dividends, enhancing the instrument’s appeal during periods of market stress.

Looking ahead, XOMA’s addition of 24 new royalty assets in 2025 expands its income base and diversifies exposure across multiple therapeutic areas. Moreover, the firm stands to benefit from Section 174 tax attributes, which could improve after‑tax cash generation as the tax code evolves. For income‑oriented investors, XOMAO presents a compelling blend of high yield, biotech sector upside, and a growing asset portfolio, making it a noteworthy candidate in a portfolio seeking stable returns amid low‑interest‑rate conditions.